Which has preferable earnings & valuation, GMED or VCYT?

Globus Medical has higher revenue and earnings than Veracyte. Globus Medical is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.73 $537.87M $3.91 20.89 Veracyte $517.15M 7.16 $66.35M $1.41 32.65

Does the media refer more to GMED or VCYT?

In the previous week, Veracyte had 7 more articles in the media than Globus Medical. MarketBeat recorded 9 mentions for Veracyte and 2 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.43 beat Veracyte's score of 0.00 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor GMED or WST?

In the previous week, West Pharmaceutical Services had 11 more articles in the media than Globus Medical. MarketBeat recorded 13 mentions for West Pharmaceutical Services and 2 mentions for Globus Medical. West Pharmaceutical Services' average media sentiment score of 0.47 beat Globus Medical's score of 0.43 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral West Pharmaceutical Services 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, GMED or RMD?

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.73 $537.87M $3.91 20.89 ResMed $5.65B 6.30 $1.52B $10.43 24.29

Is GMED or RMD more profitable?

ResMed has a net margin of 26.94% compared to Globus Medical's net margin of 17.02%. ResMed's return on equity of 25.58% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 17.02% 14.57% 12.62% ResMed 26.94% 25.58% 18.89%

Does the media refer more to GMED or RMD?

In the previous week, ResMed had 9 more articles in the media than Globus Medical. MarketBeat recorded 11 mentions for ResMed and 2 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.43 beat ResMed's score of 0.23 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ResMed 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, GMED or DXCM?

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.73 $537.87M $3.91 20.89 DexCom $4.66B 6.34 $836.30M $2.53 30.96

Is GMED or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Globus Medical's net margin of 17.02%. DexCom's return on equity of 35.94% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 17.02% 14.57% 12.62% DexCom 20.12% 35.94% 14.75%

Does the media refer more to GMED or DXCM?

In the previous week, DexCom had 16 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for DexCom and 2 mentions for Globus Medical. DexCom's average media sentiment score of 0.63 beat Globus Medical's score of 0.43 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GMED or GEHC?

In the previous week, GE HealthCare Technologies had 15 more articles in the media than Globus Medical. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 2 mentions for Globus Medical. GE HealthCare Technologies' average media sentiment score of 0.57 beat Globus Medical's score of 0.43 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 6 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Globus Medical (GMED) Competitors

$81.47 -0.19 (-0.23%)

Closing price 03:59 PM Eastern

Extended Trading

$81.42 -0.05 (-0.06%)

As of 04:05 PM Eastern

Compare

GMED vs. VCYT, WST, RMD, DXCM, and GEHC

Should you buy Globus Medical stock or one of its competitors? Globus Medical's main competitors and comparable companies include Veracyte (VCYT), West Pharmaceutical Services (WST), ResMed (RMD), DexCom (DXCM), and GE HealthCare Technologies (GEHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Globus Medical compare to Veracyte?

Globus Medical (NYSE:GMED) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Globus Medical has higher revenue and earnings than Veracyte. Globus Medical is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.73	$537.87M	$3.91	20.89
Veracyte	$517.15M	7.16	$66.35M	$1.41	32.65

Globus Medical presently has a consensus price target of $99.46, indicating a potential upside of 21.75%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 21.15%. Given Globus Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Globus Medical is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

95.2% of Globus Medical shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Globus Medical has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

In the previous week, Veracyte had 7 more articles in the media than Globus Medical. MarketBeat recorded 9 mentions for Veracyte and 2 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.43 beat Veracyte's score of 0.00 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veracyte	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veracyte has a net margin of 20.37% compared to Globus Medical's net margin of 17.02%. Globus Medical's return on equity of 14.57% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Veracyte	20.37%	9.26%	8.61%

Summary

Globus Medical beats Veracyte on 12 of the 17 factors compared between the two stocks.

How does Globus Medical compare to West Pharmaceutical Services?

Globus Medical (NYSE:GMED) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, West Pharmaceutical Services had 11 more articles in the media than Globus Medical. MarketBeat recorded 13 mentions for West Pharmaceutical Services and 2 mentions for Globus Medical. West Pharmaceutical Services' average media sentiment score of 0.47 beat Globus Medical's score of 0.43 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
West Pharmaceutical Services	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has a net margin of 17.02% compared to West Pharmaceutical Services' net margin of 16.98%. West Pharmaceutical Services' return on equity of 20.11% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
West Pharmaceutical Services	16.98%	20.11%	14.83%

Globus Medical has higher earnings, but lower revenue than West Pharmaceutical Services. Globus Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.73	$537.87M	$3.91	20.89
West Pharmaceutical Services	$3.07B	9.03	$493.70M	$7.81	50.49

Globus Medical currently has a consensus target price of $99.46, suggesting a potential upside of 21.75%. West Pharmaceutical Services has a consensus target price of $391.17, suggesting a potential downside of 0.80%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.86

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Globus Medical has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

West Pharmaceutical Services beats Globus Medical on 10 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, ResMed had 9 more articles in the media than Globus Medical. MarketBeat recorded 11 mentions for ResMed and 2 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.43 beat ResMed's score of 0.23 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ResMed	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, ResMed has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

ResMed has a net margin of 26.94% compared to Globus Medical's net margin of 17.02%. ResMed's return on equity of 25.58% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
ResMed	26.94%	25.58%	18.89%

Globus Medical presently has a consensus price target of $99.46, suggesting a potential upside of 21.75%. ResMed has a consensus price target of $243.23, suggesting a potential downside of 3.98%. Given Globus Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Globus Medical is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.73	$537.87M	$3.91	20.89
ResMed	$5.65B	6.30	$1.52B	$10.43	24.29

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 0.6% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ResMed beats Globus Medical on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

DexCom has a net margin of 20.12% compared to Globus Medical's net margin of 17.02%. DexCom's return on equity of 35.94% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
DexCom	20.12%	35.94%	14.75%

Globus Medical has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, DexCom has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Globus Medical presently has a consensus price target of $99.46, indicating a potential upside of 21.75%. DexCom has a consensus price target of $92.43, indicating a potential upside of 18.02%. Given Globus Medical's higher probable upside, equities research analysts plainly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
DexCom	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	3.04

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.73	$537.87M	$3.91	20.89
DexCom	$4.66B	6.34	$836.30M	$2.53	30.96

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, DexCom had 16 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for DexCom and 2 mentions for Globus Medical. DexCom's average media sentiment score of 0.63 beat Globus Medical's score of 0.43 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Globus Medical on 13 of the 16 factors compared between the two stocks.

How does Globus Medical compare to GE HealthCare Technologies?

Globus Medical (NYSE:GMED) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, GE HealthCare Technologies had 15 more articles in the media than Globus Medical. MarketBeat recorded 17 mentions for GE HealthCare Technologies and 2 mentions for Globus Medical. GE HealthCare Technologies' average media sentiment score of 0.57 beat Globus Medical's score of 0.43 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Globus Medical has a net margin of 17.02% compared to GE HealthCare Technologies' net margin of 9.33%. GE HealthCare Technologies' return on equity of 20.12% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
GE HealthCare Technologies	9.33%	20.12%	5.74%

GE HealthCare Technologies has higher revenue and earnings than Globus Medical. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.73	$537.87M	$3.91	20.89
GE HealthCare Technologies	$20.63B	1.56	$2.08B	$4.36	16.38

Globus Medical has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Globus Medical currently has a consensus target price of $99.46, indicating a potential upside of 21.75%. GE HealthCare Technologies has a consensus target price of $78.35, indicating a potential upside of 9.70%. Given Globus Medical's stronger consensus rating and higher probable upside, research analysts clearly believe Globus Medical is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.57

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Globus Medical beats GE HealthCare Technologies on 9 of the 17 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.94B	$5.93B	$7.58B	$23.18B
Dividend Yield	N/A	1.73%	2.49%	3.70%
P/E Ratio	20.84	26.17	274.98	28.42
Price / Sales	3.72	69.66	560.40	17.89
Price / Cash	12.52	32.52	76.25	34.10
Price / Book	2.41	5.94	10.65	4.72
Net Income	$537.87M	$148.04M	$3.51B	$1.07B
7 Day Performance	6.31%	0.30%	1.10%	0.41%
1 Month Performance	10.30%	-4.89%	-7.59%	-1.33%
1 Year Performance	29.70%	3.41%	2.65%	5.25%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.1367 of 5 stars	$81.48 -0.2%	$99.46 +22.1%	+31.1%	$10.94B	$2.94B	20.84	6,000
VCYT Veracyte	3.6765 of 5 stars	$44.02 -2.7%	$55.78 +26.7%	+32.5%	$3.64B	$517.15M	31.22	755
WST West Pharmaceutical Services	3.9096 of 5 stars	$367.33 +0.4%	$385.33 +4.9%	+42.4%	$25.76B	$3.07B	47.03	10,800	Upcoming Earnings Dividend Increase
RMD ResMed	4.1307 of 5 stars	$234.82 +2.1%	$241.69 +2.9%	-4.9%	$32.35B	$5.65B	22.51	11,370	News Coverage Upcoming Earnings
DXCM DexCom	4.8397 of 5 stars	$85.92 +2.2%	$92.22 +7.3%	+10.8%	$31.74B	$4.97B	33.96	11,000	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 10/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. VCYT, WST, RMD, DXCM, and GEHC

How does Globus Medical compare to Veracyte?

Summary

How does Globus Medical compare to West Pharmaceutical Services?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to DexCom?

Summary

How does Globus Medical compare to GE HealthCare Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. VCYT, WST, RMD, DXCM, and GEHC

How does Globus Medical compare to Veracyte?

Which has preferable earnings & valuation, GMED or VCYT?

Do analysts prefer GMED or VCYT?

Do institutionals and insiders believe in GMED or VCYT?

Which has more volatility and risk, GMED or VCYT?

Does the media refer more to GMED or VCYT?

Is GMED or VCYT more profitable?

Summary

How does Globus Medical compare to West Pharmaceutical Services?

Does the media favor GMED or WST?

Is GMED or WST more profitable?

Which has higher earnings and valuation, GMED or WST?

Do analysts rate GMED or WST?

Do insiders and institutionals have more ownership in GMED or WST?

Which has more risk & volatility, GMED or WST?

Summary

How does Globus Medical compare to ResMed?

Does the media refer more to GMED or RMD?

Which has more volatility and risk, GMED or RMD?

Is GMED or RMD more profitable?

Do analysts recommend GMED or RMD?

Which has stronger earnings and valuation, GMED or RMD?

Do insiders & institutionals have more ownership in GMED or RMD?

Summary

How does Globus Medical compare to DexCom?

Is GMED or DXCM more profitable?

Which has more volatility and risk, GMED or DXCM?

Do analysts rate GMED or DXCM?

Which has better valuation and earnings, GMED or DXCM?

Do insiders and institutionals hold more shares of GMED or DXCM?

Does the media refer more to GMED or DXCM?

Summary

How does Globus Medical compare to GE HealthCare Technologies?

Does the media refer more to GMED or GEHC?

Is GMED or GEHC more profitable?

Which has higher earnings & valuation, GMED or GEHC?

Which has more volatility & risk, GMED or GEHC?

Do analysts rate GMED or GEHC?

Do insiders & institutionals hold more shares of GMED or GEHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools